The city of Houston, Texas, currently has 22 active clinical trials seeking participants for Depression research studies.
A Trial of the Fatty Acid Amide Hydrolase Inhibitor Palmitoylethanolamide in Bipolar Depression
Recruiting
The purpose of this study is to o evaluate the antidepressant efficacy of the PEA in Bipolar Depression and the association between antidepressant response with endogenous cannabinoids and cytokine levels
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/25/2025
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Bipolar Depression
Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression
Recruiting
The purpose of the study is to assess the safety and acceptability of up to two sequential administrations of 25 mg psilocybin with additional therapeutic support in decreasing suicidality in patients with Bipolar Disorder (BD II) depression.
Gender:
ALL
Ages:
Between 25 years and 70 years
Trial Updated:
06/20/2025
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Bipolar II Disorder, Depression, Bipolar, Suicidality
Deep Brain Stimulation (DBS) Therapy for Treatment Resistant Depression
Recruiting
We propose a clinical study of medial forebrain bundle DBS as a treatment in 20 patients with treatment refractory depression (TRD). Data from the University of Bonn indicates that surgical lesions of the medical forebrain bundle can produce therapeutic benefits in patients with depressive disorders, and suggest that DBS at the same site may also reduce symptomatology in these TRD patients (Schaepfer, 2013). Depression affects up to 10% of the US population and of those at least 10-15% do not be... Read More
Gender:
ALL
Ages:
Between 22 years and 70 years
Trial Updated:
06/17/2025
Locations: UT Center of Excellence on Mood Disorders, Houston, Texas
Conditions: Major Depressive Disorder, Treatment Resistant Depression
Adjunctive Allogeneic Mesenchymal Stem Cells for Treatment-resistant Bipolar Depression
Recruiting
The overall objective of the investigators is to assess the therapeutic efficacy and tolerability of Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) isolated from hematogenous bone marrow for treatment of treatment-resistant bipolar depression patient (TRBD).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/17/2025
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Treatment-resistant Bipolar Depression
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
Recruiting
Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United States. The treatment of the depressive episodes of bipolar disorder in the pediatric population has not been as widely studied as the treatment of depressive episodes in bipolar disorder in adults, therefore pharmacotherapeutic options are limited. Given the change in disease state and safety demonstrated in adults with depressive episodes associate... Read More
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
06/16/2025
Locations: McGovern Medical School /ID# 240779, Houston, Texas +2 locations
Conditions: Depression, Bipolar I Disorder
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
Recruiting
Objectives of this study are to determine whether active VNS Therapy treatment is superior to a no stimulation control in producing a reduction in baseline depressive symptom severity, based on multiple depression scale assessment tools at 12 months from randomization.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: The University Of Texas Medical School At Houston - UT Center Of Excellence On Mood Disorders, Houston, Texas +1 locations
Conditions: Treatment Resistant Depression
Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD
Recruiting
Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2025
Locations: Brain Health Consultants and TMS Center, Houston, Texas
Conditions: Treatment Resistant Depression
Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
Recruiting
The goal of this clinical trial is to evaluate the effectiveness and safety of bilateral stimulation of the subcallosal cingulate white matter (SCCwm) using Deep Brain Stimulation (DBS) as an adjunctive treatment of non-psychotic unipolar Major Depressive Disorder (MDD) in adults.
Gender:
ALL
Ages:
Between 22 years and 70 years
Trial Updated:
06/03/2025
Locations: CHI St. Luke's Health Baylor College of Medicine Med. Ctr, Houston, Texas +1 locations
Conditions: Treatment Resistant Depression
Sequential Multiple Assignment Randomized Trial for Bipolar Depression
Recruiting
This is a sequential multiple assignment randomized trial for adults (ages \> 18) with a bipolar disorder type 1 diagnosis currently experiencing a depressive episode. It is a randomized pragmatic trial that will compare four commonly prescribed treatments for bipolar depression, which includes three FDA-approved medications (Cariprazine, Quetiapine and Lurasidone) and one antipsychotic/antidepressant combination (Aripiprazole/Escitalopram).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/21/2025
Locations: UT Health Houston Texas, Houston, Texas
Conditions: Bipolar I Disorder, Depression
Combination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer
Recruiting
To learn if Cognitive Behavior Therapy (called CBT), combined with either Bright Light Therapy (called BLT), methylphenidate, and/or melatonin, can help improve sleep and other related symptoms such as fatigue, anxiety, and depression in cancer patients. This is an investigational study. In this study, BLT, Methylphenidate and Melatonin will be compared to their placebos.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Sleep, Fatigue, Anxiety, Cancer, Depression
Functional Connectivity Alterations in Suicidal Patients Among Opioid Users
Recruiting
Suicide is the 10th leading cause of death for Americans of all ages and more people in the United States now die from suicide than die from car accidents. Although death by firearm remains the most common cause of suicide in the United States, an intentional overdose of substance usage such as prescription opioids accounts for over 5,000 suicides per year. In 2017, more than 70,000 drug overdose deaths occurred, making it the leading cause of injury-related death, and well over half (67.8%) inv... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
04/02/2025
Locations: The Menninger Clinic, Houston, Texas
Conditions: Substance Abuse, Suicide, Depression
Neurodevelopmental Outcomes in Children: Strengthening the Caregiver-Child Story
Recruiting
The main goal of this research is to help families who are experiencing food insecurity (FI) and help mothers with depression. The next goal is to provide other resources to help with household needs like rent or utility assistance, health insurance, anxiety, and depression. Our theory is that helping with food insecurity, household needs, and emotional health will help children and families.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/18/2025
Locations: Texas Children's Hospital, Houston, Texas
Conditions: Food Insecurity, Depression, Anxiety